A Phase II, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Cerebral Edema
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Balovaptan (Primary)
- Indications Brain oedema; Ischaemic stroke
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 24 Sep 2023 This trial has been discontinued in Spain.
- 03 Aug 2023 Status changed from recruiting to withdrawn prior to enrolment as per sponsor's decision.
- 03 Aug 2023 Status changed from recruiting to withdrawn prior to enrolment as per sponsor's decision.